4:30–6:00 pm

Opening Remarks, Awards and Recognition

Paul Brooks, RAPS Executive Director and Todd Chermak, Chair, RAPS Board of Directors

Opening Plenary

Daniel Diermeier: Regulatory Excellence in Times of Change and Uncertainty

Daniel Diermeier is the provost at the University of Chicago. Prior to his appointment as provost he served as the dean of the University’s Harris School of Public Policy Studies 2014–2016. He is the David Lee Shillinglaw Distinguished Service Professor in the Harris School, and in the College. He is a fellow of the American Academy of Arts and Sciences, the Guggenheim Foundation, and the Canadian Institute of Advanced Research (CIFAR).

Prior to joining the University of Chicago, Diermeier taught at the Graduate School of Business at Stanford University and the Kellogg School of Management, Northwestern University, most recently as IBM Professor of Regulation and Practice in the Department of Managerial Economics and Decision Sciences (MEDS), and director of the Ford Motor Company Center of Global Citizenship. During his time at Northwestern’s Kellogg school, he served as a distinguished faculty member for the RAPS Executive Development Program at Kellogg. He also held appointments in Economics, Political Science, Linguistics, and the School of Law at Northwestern University. 

At Northwestern, he won 13 teaching awards including the 2001 Kellogg Lavengood Professor of the Year Award and the 2013 Kellogg Alumni Professor of the Year Award. He was named among the World’s 50 Best Business School Professors and was the 2007 recipient of the Faculty Pioneer Award from the Aspen Institute named the “Oscar of Business Schools” by the Financial Times. Diermeier has been an advisor to the world’s leading companies. Clients include Accenture, BP, McDonald’s, Shell, Ernst &Young, and the Federal Bureau of Investigation.


12:15–1:15 pm

Keynote Address

US Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will deliver the opening keynote remarks at the 2017 Regulatory Convergence. Dr. Gottlieb has always been passionate and outspoken on public health policy, and we eagerly look forward to hearing directly from him on his vision for FDA and the overall direction of healthcare.

Gottlieb became the 23rd FDA commissioner in May. In his initial speech to agency staff, he called this “a time of great promise” for healthcare. Since taking over as head of FDA, he has identified addressing the national opioid addiction crisis, and increasing generic drug competition and speeding new generics to market as among his top priorities.

Gottlieb has an extensive resume, having worked in many prominent public health roles. He is a physician, medical policy expert and public health advocate who previously served as FDA’s deputy commissioner for medical and scientific affairs and before that, as a senior advisor to the commissioner. Prior to being sworn in as FDA commissioner, he was a resident fellow at the American Enterprise Institute and a clinical assistant professor at the New York University School of Medicine.

Read Scott Gottlieb's bio.